AngioDynamics (NASDAQ:ANGO) Updates FY 2027 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2027 earnings guidance on Tuesday morning. The company provided EPS guidance of -0.290–0.240 for the period, compared to the consensus earnings per share estimate of -0.190. The company issued revenue guidance of $336.0 million-$341.0 million, compared to the consensus revenue estimate of $328.7 million.

AngioDynamics Stock Up 11.3%

NASDAQ:ANGO opened at $14.47 on Thursday. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $14.80. The firm has a market capitalization of $597.89 million, a price-to-earnings ratio of -16.63 and a beta of 0.34. The stock has a fifty day simple moving average of $12.14 and a 200 day simple moving average of $11.33.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities analysts predict that AngioDynamics will post -0.26 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. HC Wainwright increased their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Canaccord Genuity Group lifted their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

Key AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported Q4 adjusted EPS of -$0.07, better than the -$0.11 estimate, while revenue of $86.61 million also topped forecasts. Article Title
• Positive Sentiment: Management said fiscal 2026 was a record year, with continued execution driving Med Tech growth and full-year profitability, which can support a stronger investor narrative. Article Title
• Positive Sentiment: AngioDynamics raised its fiscal 2027 revenue outlook to $336 million-$341 million, above consensus, signaling confidence in continued top-line growth. Article Title
• Positive Sentiment: HC Wainwright increased its price target on ANGO from $16 to $19 and reiterated a buy rating, implying further upside if execution continues. Article Title
• Neutral Sentiment: Analysts now broadly expect AngioDynamics to keep improving, but profitability remains negative and the company’s FY2027 EPS guidance is still below consensus, so investors may want to watch whether margin gains continue.

Institutional Investors Weigh In On AngioDynamics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. bought a new position in AngioDynamics in the 4th quarter worth approximately $27,000. State of Wyoming bought a new position in shares of AngioDynamics in the 2nd quarter worth $31,000. Russell Investments Group Ltd. lifted its stake in AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 3,213 shares during the period. Tower Research Capital LLC TRC grew its position in shares of AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 4,268 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in AngioDynamics by 106.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,473 shares of the medical instruments supplier’s stock worth $83,000 after acquiring an additional 3,846 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.